Research ArticleTheranostics
Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging
Ryogo Minamimoto, Ida Sonni, Steven Hancock, Shreyas Vasanawala, Andreas Loening, Sanjiv S. Gambhir and Andrei Iagaru
Journal of Nuclear Medicine May 2018, 59 (5) 803-808; DOI: https://doi.org/10.2967/jnumed.117.197624
Ryogo Minamimoto
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California
Ida Sonni
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California
Steven Hancock
2Department of Radiation Oncology, Stanford University, Stanford, California
Shreyas Vasanawala
3Radiological Sciences Laboratory, Department of Radiology, Stanford University, Stanford, California
Andreas Loening
3Radiological Sciences Laboratory, Department of Radiology, Stanford University, Stanford, California
Sanjiv S. Gambhir
4Department of Radiology, Stanford University, Stanford, California
5Department of Bioengineering, Stanford University, Stanford, California; and
6Department of Materials Science and Engineering, Stanford University, Stanford, California
Andrei Iagaru
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 5
May 1, 2018
Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging
Ryogo Minamimoto, Ida Sonni, Steven Hancock, Shreyas Vasanawala, Andreas Loening, Sanjiv S. Gambhir, Andrei Iagaru
Journal of Nuclear Medicine May 2018, 59 (5) 803-808; DOI: 10.2967/jnumed.117.197624
Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging
Ryogo Minamimoto, Ida Sonni, Steven Hancock, Shreyas Vasanawala, Andreas Loening, Sanjiv S. Gambhir, Andrei Iagaru
Journal of Nuclear Medicine May 2018, 59 (5) 803-808; DOI: 10.2967/jnumed.117.197624
Jump to section
Related Articles
Cited By...
- Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer
- A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
- A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy
- Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer
- PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer
- Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
- Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer
- Summary of the First ISMRM-SNMMI Workshop on PET/MRI: Applications and Limitations
- The Effect of Including Bone in Dixon-Based Attenuation Correction for 18F-Fluciclovine PET/MRI of Prostate Cancer